Janelle Perez and colleagues at Boston University analyzed 440 women — 261 with HIV, 179 without — from the Women's Interagency HIV Study. The work, published in The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, measured biological aging via two epigenetic clocks: a multi-tissue clock and a monocyte-specific one. Monocyte aging predicted cognitive and mood-related symptoms — anhedonia, hopelessness, feelings of failure — among women with and without HIV. The multi-tissue clock did not. [1] Yesterday's paper carried the assay sharpening on what it actually measures. Today the validation question is the news.

The phenotype split flips a longstanding clinical assumption. People with HIV often present somatic symptoms — fatigue, sleep disruption — attributed to chronic illness rather than depression. The Boston cohort shows monocyte aging tracks the non-somatic phenotype across both HIV-positive and HIV-negative women. The result narrows the biomarker question two ways: cell-type specificity (monocytes, not multi-tissue) and phenotype specificity (cognitive, not somatic). [2] A 2021 Translational Psychiatry RNA-seq study had already shown elevated biological aging in MDD versus healthy controls without finding a robust differential expression signature in PBMCs. [3] The Perez result picks up where that paper left off: the signature lives in monocyte epigenetic age, not bulk PBMC transcriptomics.

The validation cohort is what the assay needs next. The Women's Interagency HIV Study population skews older, immunocompromised, and ethnically specific. Three meta-analyses show depression is associated with elevated absolute monocyte counts across 27 studies and 2,277 patients (standardized mean difference 0.60), pointing toward a real biological signal. But a diagnostic assay that confuses cognitive depression with chronic inflammation is a treatment-stratification tool dressed as a screening test. Perez told the NYU Rory Meyers press office that long-term, the goal is precision mental-health care for high-risk populations — combining subjective experience with objective biological testing. The press release framing — "blood test for depression" — is bigger than what the assay measures. The assay may still matter. The clinical question is which RCT pairs the monocyte clock with which antidepressant trial.

-- KENJI NAKAMURA, Tokyo